Exactech, Inc. (NASDAQ:EXAC) released its quarterly earnings results on Monday. The medical equipment provider reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03), Yahoo Finance reports. The company had revenue of $61.40 million for the quarter, compared to analyst estimates of $61.78 million. Exactech had a net margin of 0.30% and a return on equity of 7.39%.
Exactech (NASDAQ:EXAC) traded up 0.12% during trading on Tuesday, reaching $41.75. The company’s stock had a trading volume of 50,547 shares. The firm has a market cap of $599.03 million, a PE ratio of 802.88 and a beta of 1.01. Exactech has a one year low of $22.20 and a one year high of $42.55. The company has a 50-day moving average of $33.78 and a 200 day moving average of $30.87.
In other Exactech news, Director Fern Watts sold 1,013 shares of the company’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $29.04, for a total value of $29,417.52. Following the sale, the director now owns 4,727 shares in the company, valued at $137,272.08. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 28.30% of the stock is currently owned by corporate insiders.
A number of research firms have issued reports on EXAC. Robert W. Baird set a $34.00 price target on Exactech and gave the company a “buy” rating in a research note on Sunday, October 15th. Zacks Investment Research downgraded Exactech from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. Gabelli downgraded Exactech from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. BidaskClub downgraded Exactech from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Finally, Sidoti downgraded Exactech from a “buy” rating to a “neutral” rating in a research note on Monday, October 23rd. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $42.00.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/10/31/exactech-inc-exac-issues-earnings-results.html.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
What are top analysts saying about Exactech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exactech Inc. and related companies.